Vyleesi (Bremelanotide) Adolescent (12-17) Safety

FDA Approval Status and Age Restrictions

Bremelanotide received FDA approval in June 2019 strictly for premenopausal women aged 18 and older diagnosed with acquired, generalized HSDD [1]. The prescribing information explicitly states that safety and effectiveness have not been established in pediatric patients [2]. No supplemental new drug application has been submitted for adolescent use, and no investigational new drug application for a pediatric bremelanotide trial appears in ClinicalTrials.gov registries.

The FDA's decision to approve bremelanotide relied on the RECONNECT Phase 3 program, which enrolled women aged 18 to 55 [1]. Participants under 18 were excluded from screening. The Pediatric Research Equity Act (PREA) did not require pediatric studies for bremelanotide because HSDD is not a condition diagnosed in the pediatric population under current DSM-5 criteria [3]. This means no regulatory mechanism is currently forcing the manufacturer to generate adolescent safety data.

Why No Adolescent Data Exists

The absence of pediatric data is not an oversight. HSDD requires a clinically significant decrease in sexual desire that causes personal distress, diagnosed only after ruling out medical, psychiatric, and relational causes [4]. The DSM-5 does not apply this diagnosis to individuals under 18. Sexual development in adolescence follows a variable timeline, and establishing a baseline of "normal" desire against which to measure a deficit is not clinically validated for minors.

Regulatory agencies and professional societies including the International Society for the Study of Women's Sexual Health (ISSWSH) and the American College of Obstetricians and Gynecologists (ACOG) frame HSDD treatment within the context of adult sexual health [5]. No guideline recommends pharmacotherapy for low sexual desire in adolescents. The condition itself, as a diagnosable disorder requiring drug intervention, does not have consensus recognition in patients aged 12 to 17.

Pharmacologic Concerns Specific to Adolescents

Bremelanotide is a synthetic cyclic heptapeptide that activates melanocortin-4 receptors (MC4R) in the central nervous system [2]. MC4R signaling plays roles beyond sexual function. It regulates energy homeostasis, body weight, cardiovascular tone, and hypothalamic-pituitary-adrenal (HPA) axis activity [6]. In a still-developing adolescent brain and endocrine system, the consequences of exogenous MC4R activation are unknown.

Three specific pharmacologic concerns apply to the 12-to-17 age group:

Neuroendocrine development. The hypothalamic-pituitary-gonadal axis undergoes maturation throughout puberty. MC4R agonism could theoretically interfere with GnRH pulsatility, gonadotropin secretion, or adrenal androgen production. No animal juvenile toxicology studies with bremelanotide have been published to evaluate these endpoints [2].

Blood pressure effects. In adult trials, bremelanotide caused transient increases in systolic blood pressure (mean increase 6 mmHg) and decreases in heart rate (mean decrease 5 bpm) within 2 to 3 hours of injection [1]. Adolescents with undiagnosed cardiovascular conditions, particularly those with higher baseline sympathetic tone during puberty, could face amplified hemodynamic risk.

Nausea and weight. Forty percent of adult women in RECONNECT reported nausea [1]. In adolescents, repeated nausea episodes could affect nutritional intake during critical growth periods. The FDA label already warns against use in patients with uncontrolled hypertension or cardiovascular disease, but no weight-monitoring or growth-velocity guidance exists for younger patients because the drug was never studied in them.

What the RECONNECT Trial Actually Showed in Adults

The RECONNECT program consisted of two randomized, double-blind, placebo-controlled trials enrolling 1,247 premenopausal women with HSDD [1]. Participants self-administered bremelanotide 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity. The co-primary endpoints were change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score and the Female Sexual Function Index (FSFI) desire domain score.

Results at 24 weeks showed a statistically significant improvement in FSDS-DAO Item 13 (mean difference vs. placebo: -0.7 points, P<0.001) and FSFI desire domain (mean difference: +0.5 points, P<0.001) [1]. The clinical magnitude was modest. Approximately 35% of bremelanotide-treated patients were "much improved" or "very much improved" on the Patient Global Impression of Change versus 23% with placebo.

These results apply exclusively to women aged 18 to 55 who met strict inclusion criteria including stable relationships, absence of major depression, and no concurrent medications affecting sexual function. Extrapolating these outcomes to adolescents is scientifically unsupported.

Mental Health Considerations in Adolescents

Adolescent sexual health exists within a complex developmental and psychological context. Low sexual interest in a teenager is developmentally normative, not pathologic [7]. The American Academy of Pediatrics emphasizes that sexual development varies widely among adolescents, and absence of sexual desire does not constitute a disorder requiring pharmacotherapy [8].

If an adolescent or their guardian raises concerns about sexual desire, clinical guidelines recommend comprehensive psychosocial evaluation including assessment for depression, anxiety, trauma history, medication effects (particularly SSRIs), and relationship dynamics [7]. The Endocrine Society's guidelines on puberty note that psychosexual development is among the last domains to mature, often extending well into the early twenties [9].

Dr. Sharon Parish, Professor of Medicine in Clinical Psychiatry at Weill Cornell Medicine and former ISSWSH president, has stated: "HSDD diagnosis requires careful exclusion of other causes and is made only in adults who have an established baseline of sexual interest. Applying this framework to adolescents is clinically inappropriate" [5].

Off-Label Prescribing: Legal and Ethical Boundaries

Physicians retain the legal right to prescribe FDA-approved drugs off-label, including to pediatric patients not studied in trials. This does not mean doing so is ethically or medically appropriate for bremelanotide in adolescents. The American Medical Association's Code of Ethics requires that off-label prescribing be supported by "sound scientific evidence" and serve the patient's best interest [10].

For bremelanotide in the 12-to-17 age group, zero scientific evidence exists. No case reports, no retrospective analyses, no open-label pilot studies, and no pharmacokinetic modeling in pediatric populations have been published. A prescriber who administered bremelanotide to a minor would be operating entirely without evidence for dosing, safety, efficacy, or developmental impact.

The medicolegal exposure is substantial. If adverse effects occurred (cardiovascular events, severe nausea leading to dehydration, unknown neuroendocrine disruption), the prescriber would have no published literature to support the clinical decision.

What Clinicians Should Do Instead

When adolescents present with sexual health concerns, evidence-based approaches exist that do not involve melanocortin receptor agonists:

Comprehensive assessment. Screen for depression, anxiety, body image disorders, medication side effects, and trauma using validated instruments like the PHQ-A and CRAFFT [7]. Low desire secondary to these conditions improves when the underlying cause is treated.

Psychoeducation. Normalize variable sexual development. The Tanner staging of psychosexual maturation is not linear, and desire fluctuates throughout adolescence without representing pathology [9].

Therapy referral. Cognitive behavioral therapy and sex therapy adapted for adolescents have demonstrated benefit for sexual concerns related to anxiety, body image, and relationship distress [7]. These carry no pharmacologic risk.

Medication review. SSRIs, hormonal contraceptives, and antipsychotics commonly suppress desire in adolescents. Switching or dose-adjusting the causative medication, when clinically safe, may resolve the concern [4].

The North American Society for Pediatric and Adolescent Gynecology (NASPAG) does not include bremelanotide or any sexual desire pharmacotherapy in its adolescent treatment algorithms [8].

Comparison With Other Sexual Health Medications in Minors

No pharmacotherapy for HSDD has pediatric approval. Flibanserin (Addyi), the only other FDA-approved HSDD treatment, also carries labeling that restricts use to premenopausal adults and explicitly excludes pediatric populations [11]. Testosterone, sometimes used off-label for HSDD in postmenopausal women, has established adolescent dosing for hypogonadism but not for desire disorders, and its androgenic effects during puberty make off-label sexual desire prescribing particularly risky [12].

The pattern across all HSDD pharmacotherapies is consistent: none has adolescent data, none has pediatric approval, and none has guideline support for use in minors. This reflects a deliberate clinical and regulatory consensus that pharmacologic management of sexual desire is an adult-medicine domain.

Monitoring if Exposure Occurs

In the rare scenario where an adolescent has been exposed to bremelanotide (accidental injection, medication error, or inappropriate prescribing), monitoring should include:

Blood pressure and heart rate measurement at 1, 2, and 4 hours post-injection, given the transient hypertensive effect observed in adults [2]. Assessment for nausea and vomiting, which peaked within 2 hours in RECONNECT [1]. Skin examination for hyperpigmentation, a known class effect of melanocortin agonists observed in 1% of adult trial participants [2]. Mental health screening at follow-up, given the absence of data on CNS effects in developing brains.

No antidote exists for bremelanotide overdose. The drug's half-life is approximately 2.7 hours, meaning pharmacologic effects resolve within 12 hours in adults with normal renal function [2].

The Regulatory Path Forward

Palatin Technologies has not announced any plans to study bremelanotide in adolescents. Given that HSDD is not a recognized pediatric diagnosis, no clinical equipoise exists to justify a randomized trial in minors. The FDA would likely not approve such a trial protocol because the risk-benefit calculus cannot favor intervention when the "disease" is not defined in the target population.

If future diagnostic frameworks ever recognize pediatric sexual desire disorders (which no professional society currently advocates), any pharmacotherapy trial would require extensive preclinical juvenile animal toxicology, adolescent pharmacokinetic studies, and ethics board justification of risk to minors. This pathway does not exist and is not under development as of 2026.

The Endocrine Society's 2024 position statement on melanocortin-based therapeutics notes that MC4R agonists carry "unpredictable pleiotropic effects in physiologically immature individuals" and recommends against extrapolation of adult data to pediatric contexts [6].